Urolog. pro Praxi, 2007; 3: 120-126

Benign prostate hypertrophy and contemporary trend in the treatment

MUDr. Jiří Klečka Ph.D, doc. MUDr. Milan Hora Ph.D
Urologická klinika, FN a LF UK, Plzeň

This article summarize contemporary oppurtunities of miniinvasive treatment of the patientes with benign prostate hypertrophy (BPH). Uptodate pharmacological traetment offers to the patients good quality of life and decreased the risk of surgical intervention. Transurethral resection of the prostate (TUR-P) is still the golden standard of the treatment of BPH. The total number of the patientes treated by TUR-P is at present slowly decreasing. The reason is boom in miniinvasive methods, witch enable reaching the same or better resultes like the TURP with advantage of minimization of bleeding and TUR- syndrome. The other advantage is very short time of leaving of the permanent catheter.

Keywords: benign prostatic hyperplasia, lower urinary tracts symptoms, bladder outlet obstruction, alpha-adrenergic receptor blockers, 5α-reductase inhibitors, minimally invasive surgical treatment

Published: July 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Klečka J, Hora M. Benign prostate hypertrophy and contemporary trend in the treatment. Urol. praxi. 2007;8(3):120-126.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams P. Objective evaluation of bladder outlet obstruction-review. Br J Urol. 1995: 76 (suppl 1): 11-15. Go to PubMed...
    2. Abrams P. In support of pressure-flow studies for evaluating men with lower urinary tract symptoms (editorial) see comments. Urology. 1994; 44: 153-155. Go to original source... Go to PubMed...
    3. American Urological Association Practice Guidelines Committee. AUA guidelines on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol. 2003: 170 (2 Pt 1): 530-547. Go to PubMed...
    4. Bautista OM, Kusek JW, Nyberg LM, et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials. 2003: 24: 224-243. Go to original source... Go to PubMed...
    5. Barry MJ, Fowler FJ Jr, 0'Leary MP, et al. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measuremerit Committee of the American Urological Association. Med Care. 1995: 33 (4 suppl): AS145-AS155.
    6. Barry MJ, Fowler FJ Jr, 0'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Cormmittee of the American Urological Association. J Urol. 1992: 148: 1549-1557; discussion 1564. Go to original source... Go to PubMed...
    7. Berry SJ, Coffey DS, Walsh PC, Ewirig LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984: 132: 474-479. Go to original source... Go to PubMed...
    8. de la Rosette JJ, Froeling FM, Alivizatos G, Debruyne FM. Laser ablation of the prostate: experience with an ultrasoun guided technique and a procedure under direct vision. Eur Urol 25, 1994: 19-24. Go to original source... Go to PubMed...
    9. de la Rosette JJ, Muschter R, Lopez MA, Gillatt D. Interstitial laser coagulation in the treatment of benign prostatic hyperplasia using a diode-laser syste with temperature feedback. Br J Urol 80, 1997: 433-38. Go to original source... Go to PubMed...
    10. de la Rosette JJ, te Slaa E, de Wild MJ, Debruyne FM. Experience with the Ultraline and urolase laser fibers: Is there any difference? World J Urol 1995, 13: 98-103. Go to original source... Go to PubMed...
    11. Dixon CM, Lasers for the treatment of benign prostatic hyperplasia. Urol Clin North Am 55, 1995: 413-422. Go to original source...
    12. Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alphal-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004: 64: 1081-1088. Go to original source... Go to PubMed...
    13. Eri LM, Wessel N, Berge V. Test-retest variation of pressure flow parameters in men with bladder outlet obstruction. J Urol. 2001; 165: 1188-1192. Go to original source... Go to PubMed...
    14. Feifer AH, Fleshner NE, Klotz L. Analytical accuracy and reliability of commonly used nutritional supplements in prostate disease. J Urol. 2002; 168: 150-154; discussion 154. Go to original source... Go to PubMed...
    15. Flam T, Spitzepfeil E, Gout A. TULIP: transurethral ultrasound guided laser-induced prostatectomy. Jd´Urol(Paris), 99, 1993: 61-66.
    16. Gilling PJ, Frauendorfer MR. Holmium laser prostatectomy: a technique in evolution. Curr Op Urol 8, 1998: 11-15. Go to original source... Go to PubMed...
    17. Gilling PJ, Cass CB, Cresswell MD. The evolution in use of the holmium laser for the treatment of benign prostatic hyperplasia. SPIE Proc 2970, 1997: 448-451. Go to original source...
    18. Girman CJ. Population-based studies of the epidemiology of benign prostatic hyperplasia. Br J Urol. 1998; 82(suppl. 1): 34-43. Go to original source... Go to PubMed...
    19. Girman CJ, Panser LA, Chut CG, et al. Natural history of prostatism: urinary flow rates in a community-based study. J Urol. 1993: 150: 887-892. Go to original source... Go to PubMed...
    20. Girman CJ, Jacobsen SJ, Rhodes T, et al. Association of health-related quality of life and benign prostatic enlargement. Eur Urol. 1999; 35: 277-284. Go to original source... Go to PubMed...
    21. Girman CJ, Jacobsen SJ, Tsukarnoto T, et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology. 1998: 51: 428-436. Go to original source... Go to PubMed...
    22. Gormley GJ, Storier E, Bruskewitz RC. et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N EnglJMed. 1992: 327: 1185-1191. Go to original source... Go to PubMed...
    23. Hai MA, Malek RS. Photoselective vaporization of the prostate: initial experience with a new 80 W KTP laser fot the treatment of benign prostatic hyperpasia. J Endourol 2003, 17: 93-96. Go to original source... Go to PubMed...
    24. Kabalin JN. Holmium: YAG laser prostatectomy: Results of a US pilot study. J Endourol 12, 1999: 575-580.
    25. Kuntzman RS, Malek RS, Barrett DM. High-power (60watt) potassium-titanyl-phosphate laser vaporization prostatectomy in living canines and in human and canine cadavers. Urology 49, 1997: 703-708. Go to original source... Go to PubMed...
    26. Lowe FC. Phytotherapy in the management of benign prostatic hyperplasia. Urology. 2001: 58(6 suppl 1): 71-76; discussion 76-77. Go to original source... Go to PubMed...
    27. Lowe FC, Dreikorn K, Borkowski A, et al. Review of placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate. 1998: 37: 187-193. Go to original source...
    28. Malek RS, Barrett DM, Kutzmann RS. High power potassium-titanyl-phosphate laser vaporization prostatectomy. J Urol. 2000 Jun; 163(6): 1730-3. Go to original source... Go to PubMed...
    29. Matsuoka K, Iida S, Tomiyasu K, Shimada A, Suekane S, Noda S. Holmium laser resection of the prostate. J Endourol 1998, 12: 279-282. (KTP/532) laser vaporization prostatectomy: 24 hours later. Urology 51, 1998: 254-256. Go to original source... Go to PubMed...
    30. McConnell JD. Medical management of benign prostatic hyperplasia with androgen suppression. Prostate Suppl. 1990: 3: 49-59. Go to original source... Go to PubMed...
    31. McConnell JD. The pathophysiology of benign prostatic hyperplasia. J Androl. 1991; 12: 356-363. Go to PubMed...
    32. McConnell J, Roehrborn C, Bautista O. et al. The long-term effects of doxazosin, finasteride and the combination on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003: 349: 2385-2396. Go to original source... Go to PubMed...
    33. Mc Cullough DL. Laser prostatectomy: free beam and contact techniques. Curr Op Urol 6, 1996: 10-13. Go to original source...
    34. Muschter R. Interstitial laser therapy. Curr Op Urol 6, 1996: 33-38. Go to original source...
    35. Roehrborn CG, Girman CJ, Rhodes T, et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology. 1997: 49: 548-557. Go to original source... Go to PubMed...
    36. Roehrborn C, McConnell J. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Walsh P, Retik A, Vaughan E, Wein A, eds. Campbell's Urology. Sth ed. Philadelphia: Saunders; 2002: 1297-1336.
    37. Roehrborn CG, Boyle P. Nickel JC, et aL Efficacy and safety of a dual inhibitor of 5-alphareductase types 1 and 2 (dutasteride) in men with benigne prostatic hyperplasia. Urology. 2002; 60: 434-441. Go to original source... Go to PubMed...
    38. Roehrborn CG, Marks LS, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004: 63: 709-715. Go to original source... Go to PubMed...
    39. Roehrborn CG, McConnell J, Bonilla J, et al. Serum prostate-specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. Urol. 2000: 163: 13-20. Go to original source... Go to PubMed...
    40. Roehrborn CG. Boyle P, Gould AL, Waldstreicher J. Serum prostate specific antigen (PSA) is a reliable surrogate for prostate volume. Urology. 1999: 53: 581-589. Go to original source... Go to PubMed...
    41. Roehrborn CG, Bruskewitz R, Nickel JC. et al. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol. 2004: 171: 1194-1198. Go to original source... Go to PubMed...
    42. Roehrborn CG, Malice M, Cook TJ. Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology. 2001: 58: 210-216. Go to original source... Go to PubMed...
    43. Roehrborn CG, McConnell JD. Lieber M. et al. Serum prostate specific antigen concentration is a powerful predictor of acute urinary retention and need for prostate related surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology. 1999: 53: 473-480. Go to original source... Go to PubMed...
    44. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003: 44: 637-649. Go to original source... Go to PubMed...
    45. Rosen RC, Cappelleri JC, Gendrario N 3rd. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int. J Impot Res. 2002: 14: 226-244. Go to original source... Go to PubMed...
    46. Rosen RC, Cappelleri JC, Smith MD. et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999: 11: 319-326. Go to original source... Go to PubMed...
    47. Rosen RC, Riley A, Wagner G, et al. The International Index of Erectile Function (IIEF): a multi-dimensional scale for assessment of erectile dysfunction. Urology. 1997: 49: 822-830. Go to original source... Go to PubMed...
    48. Russell DVV, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu Ker Biochem. 1994: 63: 25-61. Go to original source... Go to PubMed...
    49. Schwinn DA. The role of alpha-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int. 2001; 88(suppl 2): 27-34: discussion 49-50. Go to original source... Go to PubMed...
    50. Schwinn DA, Kwatra MM. Expression and regulation of alpha 1-adrenergic receptors in human tissues. Adv Pharmacol. 1998: 42: 390-394. Go to original source...
    51. Smith MS, Schambra UB, Wilson KH, et al. Alphal-adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding alpha-adrenergic receptor subtypes at four distinct levels. Brain Res Mol Brain Res. 1999: 63: 254-261. Go to original source... Go to PubMed...
    52. United Nations. World Population Prospects: The 2002 Revision (medium scenarío). New York: United Nations: 2003.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.